The Europe biosimilars market is witnessing steady expansion, driven primarily by the growing burden of chronic diseases, increasing demand for affordable therapies, and the rising number of regulatory approvals. As healthcare systems across Europe strive to balance cost containment with quality treatment, biosimilars present a viable alternative to expensive biologics. These agents offer...